Researchers looking at the genome of M. tuberculosis have discovered that HIV co-infection could be influencing how the bacteria are evolving.
Researchers have demonstrated that MRI scans could help to diagnose patients with cognitive problems due to HIV-related inflammation, presenting an alternative to lumbar punctures.
Researchers have demonstrated that utilizing nanoparticle formulated antiretrovirals could reduce the drug dose required in HIV patients, potentially cutting costs and improving treatment regimens.
Even in the era of antiretroviral treatment, mucosal candidiasis remains one of the most common manifestations in HIV-infected subjects. This editorial discusses the loss of immune control that allows mucosal candidiasis to occur.
In this review the authors discuss the limitations of current oral combination antiretroviral therapy and advances in anti-HIV nanoformulations.
